Literature DB >> 9744552

An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes.

N Masubuchi1, A P Li, O Okazaki.   

Abstract

Primary human hepatocytes contain a full complement of human drug-metabolizing enzymes and therefore represent a relevant experimental system for the evaluation of pharmacokinetic drug-drug interaction potential in human. In this study, the cytochrome P450 (CYP) induction potential of pantoprazole (PAN) was evaluated and compared to two other proton pump inhibitors (PPIs), omeprazole (OM) and lansoprazole (LAN). Primary human hepatocytes from three donors were studied. The hepatocytes were cultured for 3 days, followed by treatment for 3 days with the PPIs at 2, 5 and 10 microM. Two other known CYP inducers, 3-methylcholanthrene at 1 microM and rifampin at 50 microM, were also evaluated. Induction potentials of these chemicals for CYP1A and CYP3A were evaluated by isozyme activity and isozyme content. 7-Ethoxyresorufin-O-deethylase and testosterone 6beta-hydroxylase activities were used as endpoints for CYP1A and CYP3A, respectively. Isozyme protein contents of CYP1A and CYP3A were evaluated via Western blotting. The results showed that for CYP1A induction, the rank ordering in induction potential was consistently OM > LAN > PAN. CYP3A induction by the PPI's were observed in two of the three hepatocyte cultures, with no apparent differences in induction potency for the three compounds. Our results on CYP1A induction suggest that PAN has a lower drug-drug interaction potential than OM and LAN.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9744552     DOI: 10.1016/s0009-2797(98)00031-3

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  10 in total

Review 1.  Cytochrome P450 3A and their regulation.

Authors:  Oliver Burk; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-21       Impact factor: 3.000

Review 2.  Safety of the long-term use of proton pump inhibitors.

Authors:  Alan B R Thomson; Michel D Sauve; Narmin Kassam; Holly Kamitakahara
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

Review 3.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

4.  Exploration of the binding of proton pump inhibitors to human P450 2C9 based on docking and molecular dynamics simulation.

Authors:  Rongwei Shi; Jinyu Li; Xiaoning Cao; Xiaolei Zhu; Xiaohua Lu
Journal:  J Mol Model       Date:  2010-12-01       Impact factor: 1.810

5.  High-content analysis of constitutive androstane receptor (CAR) translocation identifies mosapride citrate as a CAR agonist that represses gluconeogenesis.

Authors:  Bryan Mackowiak; Linhao Li; Caitlin Lynch; Andrew Ziman; Scott Heyward; Menghang Xia; Hongbing Wang
Journal:  Biochem Pharmacol       Date:  2019-07-12       Impact factor: 5.858

6.  The association between proton pump inhibitor use and outcome after aneurysmal subarachnoid hemorrhage.

Authors:  Jeffrey J Fletcher; Devin L Brown; Venkatakrishna Rajajee; Teresa L Jacobs; Lauryn Rochlen; William Meurer
Journal:  Neurocrit Care       Date:  2011-12       Impact factor: 3.210

7.  The pharmacovigilance of pantoprazole: the results of postmarketing surveillance on 11 541 patients in England.

Authors:  Lynda V Wilton; Cheryl Key; Saad A W Shakir
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

8.  Stress ulcer prophylaxis in critically ill poisoned patients.

Authors:  Omid Mehrpour; Bita Dadpour; Nasim Zamani
Journal:  Daru       Date:  2012-11-27       Impact factor: 3.117

9.  Metabolism of the Marine Phycotoxin PTX-2 and Its Effects on Hepatic Xenobiotic Metabolism: Activation of Nuclear Receptors and Modulation of the Phase I Cytochrome P450.

Authors:  Jimmy Alarcan; Estelle Dubreil; Antoine Huguet; Dominique Hurtaud-Pessel; Stefanie Hessel-Pras; Alfonso Lampen; Valérie Fessard; Ludovic Le Hegarat
Journal:  Toxins (Basel)       Date:  2017-07-05       Impact factor: 4.546

10.  Effects of Calcium and Annatto Tocotrienol Supplementation on Bone Loss Induced by Pantoprazole in Male Rats.

Authors:  Kok-Yong Chin; Benjamin Ka Seng Thong; Rhivaldy Faahim Kamalulloh; Nur Vaizura Mohamad; Sok Kuan Wong; Azlan Mohd Arlamsyah; Rahma Triliana; Ima Nirwana Soelaiman
Journal:  Drug Des Devel Ther       Date:  2020-07-02       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.